ALLENTOWN — In a big win for Pennsylvania, Eli Lilly & Co. has announced plans to build a $3.5 billion drug production plant in Lehigh County.

Gov. Josh Shapiro said Lilly’s commitment is the largest private-sector life sciences investment in state history. When fully operational, the plant in Upper Macungie Township is expected to create 850 permanent jobs. The site is about 10 miles west of Allentown.

“Our mission starts with patients and delivering the medicines they need,” David A. Ricks, Lilly chair and CEO, said in a news release. “To meet increasing demand, we’re expanding our U.S. manufacturing network, with Lehigh Valley adding capacity for next-generation weight-loss medicines.”

The Pennsylvania plant is the last of four new North American manufacturing plants that Lilly said last year it planned to build. The company has since announced the other three plants will be built in Houston, Texas; Goochland County, Va.; and Huntsville, Ala.; each representing an investment of between $5 billion and $6.5 billion.

Advertise with us

Mr. Ricks said it received more than 300 proposals for sites for the four new plants.

“It was a highly-competitive process,” he said.

“We’re creating high-quality jobs and collaborating across the region — with suppliers, educators, and workforce-development partners — to make critical medicines in the U.S.,” Mr. Ricks said, adding the average salary in a Lilly facility is about $100,000 a year. “Those are high-value jobs that I can say with a lot of confidence, change the trajectory of families.”

The company said its target is to get the plant operating by 2031, although site work and construction — which itself can generate project work for hundreds — will start several years before.

With Friday’s reveal, Lilly adds a major new flag to a Big Pharma roster in Pennsylvania that already includes firms like Merck, Johnson & Johnson, GSK and Sanofi Pasteur.

Advertise with us

Mr. Shapiro noted Pennsylvania was passed over for one of Lilly’s earlier plant announcements but said his administration didn’t take no for an answer. His team pursued Lilly’s leadership, learned more about what it needed and responded with an improved proposal for the next opportunity.

“They listened, and we are grateful for that. They believed in what we had to offer here in the Commonwealth, and we are grateful for that. And in the end, I would argue, we landed an even better deal for the Lehigh Valley,” Mr. Shapiro said.

Lilly is currently the world’s highest-valued drugmaker, and it got there on the strength of its weight-loss products.

According to trade journal BioPharma Dive, Lilly’s injection-based drug Zepbound, and the version marketed separately for diabetes as Mounjaro, was the world’s top-selling pharmaceutical product through the first nine months of 2025.

Lilly hopes for U.S. Food and Drug Administration approval of its new obesity pill, orforglipron, this spring. That would allow it to quickly follow rival Novo Nordisk to market with a pill version of what have been doses delivered by daily injections to this point; Novo Nordisk started selling a pill version of its Wegovy commercially earlier this month.

Advertise with us

Lilly is also in clinical trials with a newer weight-loss drug, Retatrutide, a once-a-week injection designed for patients with obesity-related health complications that could benefit from deeper and more rapid weight loss.

Drugmakers are excited about the ability of these new weight-loss pills to reach millions of more patients across the world.

“You’re getting glucose benefits, weight benefits, improvements in blood pressure, lipids, inflammatory markers — all that in a simple once-daily pill with no restrictions on food and water and of course which we can manufacture and distribute at scale,” Ken Custer, Lilly’s president for cardiometabolic health, said at the company’s most recent quarterly earnings call.

The pills may also be an important solution in countries where it’s difficult to supply therapies that — like Zepbound and Wegovy — must be packaged, shipped and stored at cold temperatures, Mr. Ricks said.

“So we tend to think at a different magnitude about the opportunity here than historically what we’ve done with incretins,” Mr. Custer said. “In the United States there’s probably 8 [million] or 8.5 million people on incretins [now] out of maybe 170 million who might benefit. And globally that’s a much bigger number, probably measured in the high hundreds of millions or even billions.”

Advertise with us

That’s where the new manufacturing capacity comes in. Mr. Ricks said Friday the proposed Lehigh Valley plant will produce both Zepbound and, assuming it eventually wins approval for commercial use, Retatritude.

The Lehigh Valley plant will be supported by $100 million in state grants and tax credits. The state has also committed to providing a Redevelopment Assistance Capital Program award of up to $5 million to a local community college and/or technical school to help create a tailored workforce development program for Lilly’s needs.

Mr. Shapiro hailed it as a great addition to Pennsylvania’s pharmaceutical and life sciences sectors.

“Lilly’s commitment to the Lehigh Valley and to Pennsylvania will bring billions of dollars of investment and hundreds of good-paying jobs, solidifying our position as a leader in the growing life sciences industry.”

Founded in 1876 by Col. Eli Lilly, who started making drugs in Indiana after serving in the Civil War and becoming shocked by the quality of care provided to soldiers in that conflict, the company was an early mass producer of insulin and the polio vaccine.

Today, Lilly develops and makes prescription drugs across various therapeutic areas including diabetes, oncology, immunology and neuroscience. Its products are sold in approximately 95 countries.